WHO. Global Tuberculosis Control 2008: Surveillance, Planning, Financing. Geneva: WHO, 2008.
Horsburgh, CR Jr., et al.
Revisiting rates of reactivation tuberculosis: a population-based approach. American Journal of Respiratory and Critical Care Medicine
2010; 182: 420–425.
Walzl, G, et al.
Immunological biomarkers of tuberculosis. Nature Reviews Immunology
2011; 11: 343–354.
WHO. Global Tuberculosis Report
2013. Geneva: WHO, 2013.
The Technical Guidance Group of the Fifth National TB Epidemiological Survey. The Fifth national tuberculosis epidemiological survey in 2010 [in Chinese]. Chinese Journal of Antituberculosis
2012; 34: 485–508.
Di Rosa, M, et al.
Effect of interferon-gamma, interleukin-10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. Clinical Chemistry and Laboratory Medicine
2005; 43: 499–502.
Malaguarnera, L, et al.
Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. Journal of Clinical Laboratory Analysis
2005; 19: 128–132.
van Eijk, M, et al.
Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. International Immunology
2005; 17: 1505–1512.
Kologlu, T, et al.
Chitotriosidase as a possible marker of clinically evidenced atherosclerosis in dyslipidemic children. Journal of Pediatric Endocrinology & Metabolism
2014; 27: 701–708.
Debono, M, Gordee, RS
Antibiotics that inhibit fungal cell wall development. Annual Review of Microbiology
1994; 48: 471–497.
Bargagli, E, et al.
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration: International Review of Thoracic Diseases
2007; 74: 548–552.
Tasci, C, et al.
Efficacy of serum chitotriosidase activity in early treatment of patients with active tuberculosis and a negative sputum smear. Therapeutics and Clinical Risk Management
2012; 8: 369–372.
Cakir, G, et al.
Serum chitotriosidase activity in pulmonary tuberculosis: response to treatment and correlations with clinical parameters. Annals of Laboratory Medicine
2012; 32: 184–189.
WHO. Treatment of Tuberculosis: Guidelines for National Programmes, 3rd edn.
Geneva: WHO, 2003.
Chen, M, et al.
Gender and regional disparities of tuberculosis in Hunan, China. International Journal for Equity in Health
2014; 13: 32.
Deniz, O, et al.
Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clinical Biochemistry
2007; 40: 162–166.
Hollak, CE, et al.
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation
1994; 93: 1288–1292.
Korolenko, TA, et al.
Chitotriosidase as a marker of macrophage stimulation. Bulletin of Experimental Biology and Medicine
2000; 130: 948–950.
Guirado, E, Schlesinger, LS, Kaplan, G. Macrophages in tuberculosis: friend or foe. Seminars in Immunopathology
2013; 35: 563–583.
Guan, SP, et al.
Chitinases: biomarkers for human diseases. Protein and peptide letters
2009; 16: 490–498.
Di Rosa, M, et al.
Modulation of chitotriosidase during macrophage differentiation. Cell Biochemistry and Biophysics
2013; 66: 239–247.
Ramanathan, R, et al.
Serum chitotriosidase, a putative marker of chronically activated macrophages, increases with normal aging. Journal of Gerontology, Series A, Biological Sciences and Medical Sciences
2013; 68: 1303–1309.
Harlander, M, et al.
Serial chitotriosidase measurements in sarcoidosis – two to five year follow-up study. Respiratory Medicine
2014; 108: 775–782.
Bouzas, L, San Jose, E, Tutor, JC. Chitotriosidase activity in pleural effusions. Clinical Laboratory
2007; 53: 449–452.
Dupont, WD, Plummer, WD Jr. Power and sample size calculations. A review and computer program. Controlled Clinical Trials
1990; 11: 116–128.